CLC number:
On-line Access: 2022-04-22
Received: 2020-08-11
Revision Accepted: 2020-11-16
Crosschecked: 2022-04-22
Cited: 0
Clicked: 3801
Anan XU, Jeehyun LEE, Yueling ZHAO, Yuefei WANG, Xiaoli LI, Ping XU. Potential effect of EGCG on the anti-tumor efficacy of metformin in melanoma cells[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2000455 @article{title="Potential effect of EGCG on the anti-tumor efficacy of metformin in melanoma cells", %0 Journal Article TY - JOUR
表没食子儿茶素-3-没食子酸酯(EGCG)对二甲双胍抗黑素瘤细胞的潜在影响创新点:(1)EGCG联合二甲双胍对B16F10细胞活力、增殖以及STAT3/NF-κB信号通路等具有协同抑制作用;(2)EGCG联合二甲双胍在B16F10细胞凋亡和氧化应激方面具有拮抗作用;(3)利用拉曼光谱分析技术发现EGCG与二甲双胍联用对B16F10细胞的细胞核和细胞质存在差异化影响。 方法:利用CCK8测定细胞增殖,用细胞划痕实验测定细胞运动特性,利用流式细胞仪分析凋亡和细胞周期,利用免疫组织化学染色法观察细胞切片,用酶联免疫吸附试验(ELISA)测定炎症细胞因子和抗氧化酶的蛋白水平含量,用定量逆转录聚合酶链反应(qRT-PCR)检测其基因水平含量,用蛋白质印迹(western blot)探究其可能影响的细胞通路,用拉曼光谱技术从亚细胞水平探究作用机制。 结论:本研究表明EGCG与二甲双胍联合作用在抑制B16F10细胞生长、炎症水平和STAT3/NF-κB通路方面发挥部分协同效应。然而,这两种化合物对B16F10细胞凋亡和氧化应激具有拮抗作用。为了进一步证实EGCG和二甲双胍对黑色素瘤潜在的联合作用,还需要进一步研究EGCG和二甲双胍的药效学相互作用。 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]AhmadE, SargeantJA, ZaccardiF, et al., 2020. Where does metformin stand in modern day management of type 2 diabetes? Pharmaceuticals, 13(12):427. [2]BalkwillF, MantovaniA, 2001. Inflammation and cancer: back to Virchow? Lancet, 357(9255):539-545. [3]CaltagironeS, RossiC, PoggiA, et al., 2000. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer, 87(4):595-600. [4]CerezoM, TichetM, AbbeP, et al., 2013. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther, 12(8):1605-1615. [5]ChaeYK, AryaA, MalecekMK, et al., 2016. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget, 7(26):40767-40780. [6]ChaiEZP, ShanmugamMK, ArfusoF, et al., 2016. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther, 162:86-97. [7]ChenK, QianWK, JiangZD, et al., 2017. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer, 16:131. [8]ChenSN, ZhuXM, LaiXF, et al., 2014. Combined cancer therapy with non-conventional drugs: all roads lead to AMPK. Mini Rev Med Chem, 14(8):642-654. [9]ChikaraS, NagaprashanthaLD, SinghalJ, et al., 2018. Oxidative stress and dietary phytochemicals: role in cancer chemoprevention and treatment. Cancer Lett, 413:122-134. [10]CourtoisS, LehoursP, BessèdeE, 2019. The therapeutic potential of metformin in gastric cancer. Gastric Cancer, 22(4):653-662. [11]de Souza NetoFP, BernardesSS, MarinelloPC, et al., 2017. Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma. Melanoma Res, 27(6):536-544. [12]EllisLZ, LiuWM, LuoYC, et al., 2011. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem Biophys Res Commun, 414(3):551-556. [13]FarhoodB, NajafiM, SalehiE, et al., 2019. Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy. J Cell Biochem, 120(1):71-76. [14]FruehaufJP, MeyskensFL, 2007. Reactive oxygen species: a breath of life or death? Clin Cancer Res, 13(3):789-794. [15]FujikiH, SueokaE, WatanabeT, et al., 2015. Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds. J Cancer Prev, 20(1):1-4. [16]HanahanD, WeinbergRA, 2011. Hallmarks of cancer: the next generation. Cell, 144(5):646-674. [17]HartPC, ChiyodaT, LiuXJ, et al., 2019. SPHK1 is a novel target of metformin in ovarian cancer. Mol Cancer Res, 17(4):870-881. [18]HartmanRI, LinJY, 2019. Cutaneous melanoma—a review in detection, staging, and management. Hematol Oncol Clin North Am, 33(1):25-38. [19]HeathJR, RibasA, MischelPS, 2016. Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov, 15(3):204-216. [20]HodgesV, TucciM, BenghuzziH, 2015. The effects of metformin and EGCG on PANC-1 cell survival. Biomed Sci Instrum, 51:393-399. [21]Iglesias-PenaN, ParadelaS, Tejera-VaquerizoA, et al., 2019. Cutaneous melanoma in the elderly: review of a growing problem. Actas Dermosifiliogr, 110(6):434-447. [22]JanjetovicK, Harhaji-TrajkovicL, Misirkic-MarjanovicM, et al., 2011. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol, 668(3):373-382. [23]JauneE, RocchiS, 2018. Metformin: focus on melanoma. Front Endocrinol, 9:472. [24]KarinM, 2006. Nuclear factor-κB in cancer development and progression. Nature, 441(7092):431-436. [25]KimDS, ParkSH, KwonSB, et al., 2004. (-)-Epigallocatechin-3-gallate and hinokitiol reduce melanin synthesis via decreased MITF production. Arch Pharm Res, 27(3):334-339. [26]KimK, YangWH, JungYS, et al., 2020. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity. BMB Rep, 53(10):512-520. [27]KlaunigJE, 2018. Oxidative stress and cancer. Curr Pharm Des, 24(40):4771-4778. [28]LeeJH, KishikawaM, KumazoeM, et al., 2010. Vitamin A enhances antitumor effect of a green tea polyphenol on melanoma by upregulating the polyphenol sensing molecule 67-kDa laminin receptor. PLoS ONE, 5(6):e11051. [29]LiF, ZhangJW, ArfusoF, et al., 2015. NF-κB in cancer therapy. Arch Toxicol, 89(5):711-731. [30]LiK, ZhangTT, WangF, et al., 2018. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene, 37(22):2967-2981. [31]LiuMH, ZhangZ, WangH, et al., 2019. Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2. Int J Biol Sci, 15(3):617-627. [32]LordSR, ChengWC, LiuD, et al., 2018. Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metab, 28(5):679-688.e4. [33]LuCC, ChiangJH, TsaiFJ, et al., 2019. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol, 54(4):1271-1281. [34]MaLW, WeiJW, WanJH, et al., 2019. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res, 38(1):77. [35]MignoletA, WoodBR, GoormaghtighE, 2018. Intracellular investigation on the differential effects of 4 polyphenols on MCF-7 breast cancer cells by Raman imaging. Analyst, 143:258-269. [36]MillerKD, NogueiraL, MariottoAB, et al., 2019. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin, 69(5):363-385. [37]MovasaghiZ, RehmanS, RehmanIU, 2007. Raman spectroscopy of biological tissues. Appl Spectrosc Rev, 42(5):493-541. [38]NicolucciA, CharbonnelB, GomesMB, et al., 2019. Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme. Diabetes, Obes Metab, 21(11):2474-2485. [39]NiehrF, von EuwE, AttarN, et al., 2011. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med, 9:76. [40]NihalM, AhsanH, SiddiquiIA, et al., 2009. (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle, 8(13):2057-2063. [41]NihalM, RoelkeCT, WoodGS, 2010. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). Pharm Res, 27(6):1103-1114. [42]PashaM, SivaramanSK, FrantzR, et al., 2019. Metformin induces different responses in clear cell renal cell carcinoma Caki cell lines. Biomolecules, 9(3):113. [43]PerryG, RainaAK, NunomuraA, et al., 2000. How important is oxidative damage? Lessons from Alzheimer’s disease. Free Radical Bio Med, 28(5):831-834. [44]RavindranathMH, RamasamyV, MoonS, et al., 2009. Differential growth suppression of human melanoma cells by tea (Camellia sinensis) epicatechins (ECG, EGC and EGCG). Evid Based Complement Alternat Med, 6(4):523-530. [45]SabryD, AbdelaleemOO, el Amin AliAM, et al., 2019. Anti-proliferative and anti-apoptotic potential effects of epigallocatechin-3-gallate and/or metformin on hepatocellular carcinoma cells: in vitro study. Mol Biol Rep, 46(2):2039-2047. [46]SchumacherB, GarinisGA, HoeijmakersJHJ, 2008. Age to survive: DNA damage and aging. Trends Genet, 24(2):77-85. [47]ShenQ, TianF, JiangP, et al., 2009. EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J Huazhong Univ Sci Technol Med Sci, 29:771. [48]SiegelRL, MillerKD, JemalA, 2019. Cancer statistics, 2019. CA Cancer J Clin, 69(1):7-34. [49]SunRJ, ZhaiRR, MaCL, et al., 2020. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway. Cancer Med, 9(3):1141-1151. [50]SunY, HuangLQ, MackenzieGG, et al., 2011. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther, 338(3):775-783. [51]SuzukiK, TakeuchiO, SuzukiY, et al., 2019. Mechanisms of metformin’s anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma. Int J Oncol, 54(2):764-772. [52]TangGJ, GuoJF, ZhuYP, et al., 2018. Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation. Int J Oncol, 52(6):1899-1911. [53]TaniguchiK, KarinM, 2018. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol, 18(5):309-324. [54]TaniguchiS, FujikiH, KobayashiH, et al., 1992. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett, 65(1):51-54. [55]TomicT, BottonT, CerezoM, et al., 2011. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis, 2(9):e199. [56]ToyokuniS, OkamotoK, YodoiJ, et al., 1995. Persistent oxidative stress in cancer. FEBS Lett, 358(1):1-3. [57]TrachoothamD, AlexandreJ, HuangP, 2009. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 8(7):579-591. [58]WangL, LiK, LinXJ, et al., 2019. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. Cancer Lett, 450:22-31. [59]WatanabeT, KuramochiH, TakahashiA, et al., 2012. Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells. J Cancer Res Clin Oncol, 138(5):859-866. [60]WeiR, PensoNEC, HackmanRM, et al., 2019a. Epigallocatechin-3-gallate (EGCG) suppresses pancreatic cancer cell growth, invasion, and migration partly through the inhibition of Akt pathway and epithelial-mesenchymal transition: enhanced efficacy when combined with gemcitabine. Nutrients, 11(8):1856. [61]WeiR, HackmanRM, WangYF, et al., 2019b. Targeting glycolysis with epigallocatechin-3-gallate enhances the efficacy of chemotherapeutics in pancreatic cancer cells and xenografts. Cancers, 11(10):1496. [62]WoltersS, SchumacherB, 2013. Genome maintenance and transcription integrity in aging and disease. Front Genet, 4:19. [63]WuY, LinY, LiuHJ, et al., 2008. Inhibition of invasion and up-regulation of E-cadherin expression in human malignant melanoma cell line A375 by (-)-epigallocatechin-3-gallate. J Huazhong Univ Sci Technolog Med Sci, 28(3):356-359. [64]XuN, ZhuPP, LiangJ, et al., 2019. Label-free Raman spectroscopy monitoring of cytotoxic response induced by a telomerase inhibitor. Sens Actuat B Chem, 293:1-10. [65]XuP, YanF, ZhaoYL, et al., 2020. Green tea polyphenol EGCG attenuates MDSCs-mediated immunosuppression through canonical and non-canonical pathways in a 4T1 murine breast cancer model. Nutrients, 12(4):1042. [66]YamadaS, TsukamotoS, HuangYH, et al., 2016. Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. Sci Rep, 6:19225. [67]YangCS, WangX, LuG, et al., 2009. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer, 9(6):429-439. [68]YuCX, JiaoY, XueJ, et al., 2017. Metformin sensitizes non-small cell lung cancer cells to an epigallocatechin-3-gallate (EGCG) treatment by suppressing the Nrf2/HO-1 signaling pathway. Int J Biol Sci, 13(12):1560-1569. [69]YuH, KortylewskiM, PardollD, 2007. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 7(1):41-51. [70]YuH, PardollD, JoveR, 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 9(11):798-809. [71]YuX, ZhouW, WangHM, et al., 2019. Transdermal metformin hydrochloride-loaded cubic phases: in silico formulation optimization, preparation, properties, and application for local treatment of melanoma. Drug Deliv, 26(1):376-383. [72]ZhangJL, LeiZ, HuangZN, et al., 2016. Epigallocatechin-3-gallate (EGCG) suppresses melanoma cell growth and metastasis by targeting TRAF6 activity. Oncotarget, 7(48):79557-79571. [73]ZhangYP, PengGY, HsuehEC, 2015. Abstract 1196: enhancement of anti-melanoma effect of BRAF and MEK inhibition bymetformin. Cancer Res, 75(15):1196. [74]ZhouY, HilemanEO, PlunkettW, et al., 2003. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood, 101(10):4098-4104. [75]ZordokyBNM, BarkD, SoltysCL, et al., 2014. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta, 1840(6):1943-1957. [76]ZouG, BaiJ, LiDD, et al., 2019. Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells. Exp Ther Med, 18(3):2086-2094. Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>